RT Journal Article SR Electronic T1 Rare genetic variants in SEC24D modify orofacial cleft phenotypes JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.03.24.23287714 DO 10.1101/2023.03.24.23287714 A1 Curtis, Sarah W. A1 Carlson, Jenna C. A1 Beaty, Terri H. A1 Murray, Jeffrey C. A1 Weinberg, Seth M. A1 Marazita, Mary L. A1 Cotney, Justin L. A1 Cutler, David J. A1 Epstein, Michael P. A1 Leslie, Elizabeth J. YR 2023 UL http://medrxiv.org/content/early/2023/03/27/2023.03.24.23287714.abstract AB As one of the most common structural birth defects, orofacial clefts (OFCs) have been studied for decades, and recent studies have demonstrated that there are genetic differences between the different phenotypic presentations of OFCs. However, the contribution of rare genetic variation genome-wide to different subtypes of OFCs has been understudied, with most studies focusing on common genetic variation or rare variation within targeted regions of the genome. Therefore, we used whole-genome sequencing data from the Gabriella Miller Kids First Pediatric Research Program to conduct a gene-based burden analysis to test for genetic modifiers of cleft lip (CL) vs cleft lip and palate (CLP). We found that there was a significantly increased burden of rare variants in SEC24D in CL cases compared to CLP cases (p=6.86×10−7). Of the 15 variants within SEC24D, 53.3% were synonymous, but overlapped a known craniofacial enhancer. We then tested whether these variants could alter predicted transcription factor binding sites (TFBS), and found that the rare alleles destroyed binding sites for 9 transcription factors (TFs), including Pax1 (p=0.0009), and created binding sites for 23 TFs, including Pax6 (p=6.12×10−5) and Pax9 (p= 0.0001), which are known to be involved in normal craniofacial development, suggesting a potential mechanism by which these synonymous variants could have a functional impact. Overall, this study demonstrates that rare genetic variation contributes to the phenotypic heterogeneity of OFCs and suggests that regulatory variation may also contribute and warrant further investigation in future studies of genetic variants controlling risk to OFC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThese studies are part of the Gabriella Miller Kids First Pediatric Research Program, supported by the Common Fund of the Office of the Director of the National Institutes of Health (NIH). Sequencing of the European trios was completed at Washington University McDonnell Genome Institute (3U54HG003079-12S1 and X01-HL132363 and the Colombian and Taiwanese trios were sequenced at the Broad Institute Sequencing Center (U24-HD090743). The sequencing centers plus the Kids First Data Resource Center, supported by the NIH Common Fund through grant U2CHL138346, provided technical and analytical support of this project. This work was supported by grants from the National Institutes of Health (NIH) including: F32-DE032260 [SWC], R00-DE025060 [EJL], R01-DE028342 [EJL], R03-DE030118 [EJL], R21- DE029698 [MPE], X01-HG007485 [MLM, EF], R01-DE016148 [MLM, SMW], U01-DE024425 [MLM], R37- DE008559 [JCM, MLM], R01-DE009886 [MLM], R21-DE016930 [MLM], R01- DE012472 [MLM], R01-DE014581 [THB], U01-DE018993 [THB], U01-DE020078; R01-DE027023 [SMW].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRBs of Emory University, the University of Pittsburgh, the University of Iowa, and the IRBs at local recruitment sites gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data is available in the database of Genotypes and Phenotypes (dbGaP; European trios, dbGaP: phs001168.v2.p2; Colombian trios, dbGaP: phs001420.v1.p1; Taiwanese trios, dbGaP: phs000094.v1.p1) and from the Kids First Data Resource Center.